Abstract
Ligustrazine is a principal ingredient of chuanxiong. Concerns regarding the evaluation of the effectiveness of ligustrazine in the treatment of UA have resulted in a meta-analysis combined with recent clinical evidence. Seven computer databases that included the China hospital knowledge database (CHKD), Wanfang Med Online, the Chinese medical journal database (CMJD), PubMed, Cochrane, Embase (Ovid), and Medline (Ovid) were systematically searched. We included randomized controlled trials and quasi-randomized controlled trials. Our systematic review identified 16 RCTs that met our eligibility criteria. Ligustrazine combined with conventional medicine was associated with an increased rate of marked improvement in symptoms and an increased rate of marked improvement of ECG compared with conventional Western medicine alone. Additionally, the use of ligustrazine was associated with significant trends in the reduction of the consumption of nitroglycerin and the level of fibrinogen when compared with conventional Western medicine alone. No firm results were found between the intervention and the control method groups in the reduction of the time of onset or the frequency of acute attack angina due to the high level of heterogeneity. In conclusion, our meta-analysis found that ligustrazine was associated with some benefits for people with unstable angina.
Highlights
United Nations member states have agreed to reduce premature cardiovascular disease (CVD) mortality 25% by 2025
A total of 1591 trials were identified by database searching and other sources
The frequency of acute attack angina was reported in three RCTs involving 331 participants, and these studies compared the frequency of acute attack angina between ligustrazine and conventional medicine (MD = −0.53, 95% confidence intervals (CIs) (−1.08, −0.03))
Summary
United Nations member states have agreed to reduce premature cardiovascular disease (CVD) mortality 25% by 2025. Conventional medicine has consisted of antiplatelet agents, anticoagulant agents, nitrates, beta-adrenergic blockers, calcium channel blockers, and inhibitors of the renin-angiotensin-aldosterone system [9] These treatments are widely used in the acute relief of secondary angina pectoris and the long-term prophylactic management of angina pectoris, chuanxiong might be useful for UA and for increased safety. It has been shown to play a critical role in cardiovascular treatments, mediated by inhibition of Ca2+ influx and by the release of intracellular Ca2+ [11, 12] It significantly inhibits L-type calcium current in a concentration-dependent manner to make vasodilatory effect, to improve the situation of myocardium ischemia [13, 14]. Adverse events are death, lifethreatening events, crippling, disabling, teratogenic effects, requiring special events, and hospitalization
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
